Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $17.96M. Across the group, the median move over the past trading day is +6.40%. Price change over the past year runs from −4.5% to +6126.0% across the middle 80 percent of the group, with a median of +128.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 0IIM.L | Esperion Therapeutics, Inc. | $3.19 | +0.14% | −14.28% | +44.65% |
| VYNE | VYNE Therapeutics Inc | $28.56 | +3080.40% | +4824.14% | +8660.74% |
| CMMB | Chemomab Therapeutics Ltd. | $2.59 | +81.12% | +44.69% | −25.57% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.33 | +710.86% | +426.12% | +211.51% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.